Hanx Bio

Hanx Bio, based in Wuhan, China, is a biopharmaceutical company focused on developing innovative therapeutics that address critical health challenges within the biotechnology sector. Founded in 2014, Hanx Bio specializes in biopharmaceuticals aimed at treating chronic illnesses and infectious diseases. The company has successfully raised HKD 93. 4 mn in its latest funding round, the Pre-IPO round, with investors including Guotai Junan Securities and Main Source Capital.

Its headquarters are located in Wuhan, China, where it has conducted five deals, the most recent of which was completed on December 23, 2025. Hanx Bio specializes in innovative biopharmaceutical products designed to address critical health challenges within the biotechnology sector. The company focuses on developing therapeutics that target specific diseases, leveraging advanced technologies to enhance efficacy and safety. Hanx Bio’s core product offerings include proprietary biologics and therapeutics aimed at treating chronic illnesses, autoimmune disorders, and infectious diseases.

These products are meticulously designed to meet the needs of healthcare providers, patients, and research institutions, enhancing treatment outcomes and overall patient care. Hanx Bio markets its products primarily in North America, Europe, and select regions in Asia, serving a diverse client base that includes hospitals, clinics, and pharmaceutical distributors. Hanx Bio generates revenue through a multifaceted transaction structure that includes direct sales to healthcare providers and B2B partnerships with pharmaceutical wholesalers. The company’s flagship products operate under a subscription and licensing model that offers clients continuous access to the latest therapeutic innovations, with structured agreements outlining pricing plans based on volume purchases and long-term partnerships.

This strategy ensures a stable revenue source and emphasizes collaborative relationships with healthcare institutions to facilitate the distribution of its products effectively. Hanx Bio's future growth strategy includes the launch of new therapeutics designed to address various health issues, with upcoming releases planned for late 2025. The company aims to expand its market presence in Europe and Southeast Asia by 2026. Recent funding of HKD 586.

3 million from its IPO will support these initiatives, including the development of new products and geographic market expansion.